India's cheap weight-loss drugs could reshape global obesity fight
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"Prices are expected to fall sharply."
— Sheetal Sapale , Other
"It is great that these will become cheaper so that more of the diabetic and obese Indian population can access them."
— Muffazal Lakdawala , Other
Key People
Locations
All Coverage
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Similar Stories
Related coverage based on topic and tags
Eli Lilly launches oral weight-loss pill Foundayo in UK - Reuters
Eli Lilly launches oral weight-loss pill Foundayo in UK Reuters
August 23, 2026 at 11:07 PMMore US employers to drop weight-loss drugs in 2027, as healthcare costs increase - Reuters
More US employers to drop weight-loss drugs in 2027, as healthcare costs increase Reuters
August 25, 2026 at 03:46 PMChina's drug regulator accepts Novo Nordisk's application for oral Wegovy - Reuters
China's drug regulator accepts Novo Nordisk's application for oral Wegovy Reuters
August 27, 2026 at 03:47 AMEXCLUSIVE: India proposes front-of-pack warning labels for packaged foods after public outcry - Reuters
EXCLUSIVE: India proposes front-of-pack warning labels for packaged foods after public outcry Reuters
August 28, 2026 at 04:24 PMIndia wanted red flags on chip packets and soda. Big Food fought back. - Reuters
India wanted red flags on chip packets and soda. Big Food fought back. Reuters
August 25, 2026 at 04:05 AMUS FDA approves Lilly's Mounjaro to reduce cardiovascular risk - Reuters
US FDA approves Lilly's Mounjaro to reduce cardiovascular risk Reuters
August 28, 2026 at 06:38 PM